Literature DB >> 11207329

The psychotic phenomenon in probable Alzheimer's disease: a positron emission tomography study.

O L Lopez1, G Smith, J T Becker, C C Meltzer, S T DeKosky.   

Abstract

Positron emission tomography was used to examine the mechanisms of the psychotic phenomenon in Alzheimer's disease (AD). Data from 2 patients with delusions and 2 with hallucinations were compared with those of 5 AD patients without psychosis. The patients with paranoid delusions had diminished relative regional cerebral blood flow (rel-CBF) in the left dorsolateral prefrontal and left medial temporal cortices. The patients with visual hallucinations showed diminished rel-CBF in the right parietal, left medial temporal, and left dorsolateral prefrontal cortices. These findings support the hypothesis that a frontal-temporal abnormality is associated with paranoid delusions in AD. By contrast, visual hallucinations are associated with parietal as well as frontal and temporal lobe dysfunction. In these patients, a left prefrontal-temporal cortex dysfunction appears to be a common denominator for the development of the psychotic phenomenon in AD.

Entities:  

Mesh:

Year:  2001        PMID: 11207329     DOI: 10.1176/jnp.13.1.50

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  18 in total

1.  Behavioral disturbance in dementia.

Authors:  Abhilash K Desai; Lori Schwartz; George T Grossberg
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

Review 2.  Diagnosing schizophrenia circa 2005: how and why?

Authors:  Laurie M McCormick; Michael Flaum
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

3.  An aqueous orally active vaccine targeted against a RAGE/AB complex as a novel therapeutic for Alzheimer's disease.

Authors:  Scott J Webster; Shyamala Mruthinti; William David Hill; Jerry J Buccafusco; Alvin V Terry
Journal:  Neuromolecular Med       Date:  2012-03-14       Impact factor: 3.843

Review 4.  Clinical and neurocognitive aspects of hallucinations in Alzheimer's disease.

Authors:  Mohamad El Haj; Jean Roche; Renaud Jardri; Dimitrios Kapogiannis; Karim Gallouj; Pascal Antoine
Journal:  Neurosci Biobehav Rev       Date:  2017-02-21       Impact factor: 8.989

5.  Accelerated atrophy in dopaminergic targets and medial temporo-parietal regions precedes the onset of delusions in patients with Alzheimer's disease.

Authors:  Riccardo Manca; Jose Manuel Valera-Bermejo; Annalena Venneri
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-05-13       Impact factor: 5.270

6.  Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study.

Authors:  Katherine A Treiber; Constantine G Lyketsos; Chris Corcoran; Martin Steinberg; Maria Norton; Robert C Green; Peter Rabins; David M Stein; Kathleen A Welsh-Bohmer; John C S Breitner; JoAnn T Tschanz
Journal:  Int Psychogeriatr       Date:  2008-02-21       Impact factor: 3.878

7.  Neuropsychiatric symptoms and global functional impairment along the Alzheimer's continuum.

Authors:  Lauren P Wadsworth; Natacha Lorius; Nancy J Donovan; Joseph J Locascio; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Gad A Marshall
Journal:  Dement Geriatr Cogn Disord       Date:  2012-08-28       Impact factor: 2.959

8.  Regional cortical thinning predicts worsening apathy and hallucinations across the Alzheimer disease spectrum.

Authors:  Nancy J Donovan; Lauren P Wadsworth; Natacha Lorius; Joseph J Locascio; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Gad A Marshall
Journal:  Am J Geriatr Psychiatry       Date:  2013-07-24       Impact factor: 4.105

Review 9.  Psychosis in Alzheimer's disease.

Authors:  Patrick S Murray; Sanjeev Kumar; Mary Ann A Demichele-Sweet; Robert A Sweet
Journal:  Biol Psychiatry       Date:  2013-10-06       Impact factor: 13.382

10.  Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease.

Authors:  Gwenn S Smith; Elisse Kramer; Yilong Ma; Carol R Hermann; Vijay Dhawan; Thomas Chaly; David Eidelberg
Journal:  Brain       Date:  2009-01-19       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.